GLP-1glp-1type 2 diabetesdiabetic foot ulceramputation

GLP-1 use tied to lower amputation risk in diabetic foot ulcer cohort

The association appeared only in patients without coded peripheral arterial disease, where five-year amputation hazard fell to 0.21 versus other glucose-lowering therapy.

By Maren Holt · Senior Reporter, GLP-1

Oct 13 20:00 ETSource: Diabetes, obesity & metabolism

The wire

01In 21,325 propensity-matched pairs from TriNetX, GLP-1 receptor agonist users with type 2 diabetes and foot ulcer had a five-year lower-extremity amputation hazard ratio of 0.60, and all-cause mortality HR 0.48.
02Effect modification was stark: HR 0.21 in the no-PAD stratum versus 0.97 where PAD was coded, a signal clinicians managing diabetic foot ulcers may want to track.
03Authors call the retrospective, observational findings hypothesis-generating and requiring prospective confirmation; six pre-specified sensitivity analyses were run, and broadening the PAD definition attenuated the result.

From the source

GLP-1 Receptor Agonist Therapy Is Associated With Lower Risk of Lower Extremity Amputation in Adults With Type 2 Diabetes and Foot Ulcer Without Coded Peripheral Arterial Disease: A Hypothesis-Generating Real-World Cohort Study
Diabetes, obesity & metabolism · 2026 Oct 14 · Robinson H, Yassin M, Robinson D et al.

Read at pubmed.ncbi.nlm.nih.gov

Source URL https://pubmed.ncbi.nlm.nih.gov/42875725/